Skip to main content

Table 5 Influence of different combined oral contraceptive formulations in the anthropometric parameters of polycystic ovary syndrome

From: Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

COC formulation

Number of studies

Before

Md (1st – 3rd)

After

Md (1st – 3rd)

∆

p*

BW

 EE 35 μg / CPA 2 mg

02

69.6 (67.7–80.2)

69.8 (67.1–72.3)

+0.2

0.754

 EE 30 μg / DRSP 3 mg

04

63.5 (60.1–66.2)

63.0 (61.8–65.1)

−0.5

0.465

 EE 30 μg / CMA 2 mg

03

57.5 (55.9–59.7)

58.1 (56.7–61.3)

+0.4

0.653

 EE 30 μg / DSG 75–150 μg

02

67.0 (66.1–67.9)

68.2 (67.5–70.1)

+1.2

0.900

BMI (kg/m2)

 EE 35 μg / CPA 2 mg

13

24.0 (22.6–27.3)

23.1 (22.1–26.9)

−0.9

0.151

 EE 30 μg / DRSP 3 mg

17

23.4 (22.2–26.4)

24.5 (22.7–26.3)

+1.1

0.924

 EE 30 μg / CMA 2 mg

05

22.5 (22.2–23.3)

22.7 (22.5–23.4)

+0.2

0.138

 EE 30 μg / DSG 75–150 μg

07

26.7 (24.4–30.1)

27.2 (23.8–29.2)

+0.5

0.262

WC (cm)

 EE 30 μg / DRSP 3 mg

03

76.7 (74.0–79.4)

77.6 (75.4–79.2)

+0.9

0.810

 EE 30 μg / CMA 2 μg

02

78.3 (78.0–78.7)

72.2 (77.0–77.4)

−1.1

0.089

 EE 30 μg / NGM 180–250 μg

03

80.3 (63.3–97.3)

79.7 (63.7–95.7)

−0.6

0.179

WHR

 EE 35 μg / CPA 2 mg

07

0.80 (0.74–0.91)

0.79 (0.74–0.88)

−0.01

0.179

 EE 30 μg / DRSP 3 mg

12

0.78 (0.76–0.81)

0.75 (0.74–0.81)

−0.03

0.241

 EE 30 μg / CMA 2 mg

02

0.73 (0.51–0.095)

0.78 (0.75–0.81)

−0.05

0.317

 EE 30 μg / DSG 75–150 μg

04

0.81 (0.75–0.82)

0.80 (0.75–0.82)

−0.01

0.654

 EE 30 μg / NGM 180–250 μg

02

0.80 (0.74–0.86)

0.78 (0.75–0.81)

−0.02

0.317

FM (kg)

 EE 30 μg / DRSP 3 mg

03

21.0 (19.20–22.0)

22.9 (20.9–24.8)

+1.9

0.108

  1. COC combined oral contraceptive, Md (1st – 3rd) median, first and third quartiles, BW body weight, BMI body mass index, WC waist circumference, WHR waist-hip ratio, FM fat mass, EE ethinylestradiol, CPA cyproterone acetate, DRSP drospirenone, CMA chlormadinone acetate, DSG desogestrel, NGM norgestimate
  2. p* Wilcoxon signed- ranks test